Drug Profile

Research programme: small molecule therapeutics - KayoThera

Latest Information Update: 28 Aug 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Princeton University
Developer KayoThera
Class Antihyperglycaemics; Antineoplastics; Small molecules
Mechanism of Action Aldehyde dehydrogenase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Type 2 diabetes mellitus
Research Cancer

Most Recent Events

20 Jul 2023 Early research in Cancer in USA (PO)
19 Jul 2023 KayoThera receives SBIR grant from the National Institutes of health to advance lead diabetes and oncology programs
18 May 2023 Preclinical trials in Type 2 diabetes mellitus in USA (PO)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com